CA2494069A1 - Pellicle-resistant gelatin capsule - Google Patents
Pellicle-resistant gelatin capsule Download PDFInfo
- Publication number
- CA2494069A1 CA2494069A1 CA002494069A CA2494069A CA2494069A1 CA 2494069 A1 CA2494069 A1 CA 2494069A1 CA 002494069 A CA002494069 A CA 002494069A CA 2494069 A CA2494069 A CA 2494069A CA 2494069 A1 CA2494069 A1 CA 2494069A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- gelatin
- dosage form
- drug
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- AIDS & HIV (AREA)
- Immunology (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39977602P | 2002-07-31 | 2002-07-31 | |
| US39986302P | 2002-07-31 | 2002-07-31 | |
| US39986202P | 2002-07-31 | 2002-07-31 | |
| US39980802P | 2002-07-31 | 2002-07-31 | |
| US60/399,862 | 2002-07-31 | ||
| US60/399,776 | 2002-07-31 | ||
| US60/399,808 | 2002-07-31 | ||
| US60/399,863 | 2002-07-31 | ||
| PCT/US2003/024042 WO2004010972A2 (en) | 2002-07-31 | 2003-07-31 | Pellicle-resistant gelatin capsule |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2494069A1 true CA2494069A1 (en) | 2004-02-05 |
Family
ID=31192378
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002493974A Abandoned CA2493974A1 (en) | 2002-07-31 | 2003-07-31 | Pharmaceutical dosage form comprising a sulfite compound |
| CA002494358A Abandoned CA2494358A1 (en) | 2002-07-31 | 2003-07-31 | Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
| CA002494069A Abandoned CA2494069A1 (en) | 2002-07-31 | 2003-07-31 | Pellicle-resistant gelatin capsule |
| CA002493980A Abandoned CA2493980A1 (en) | 2002-07-31 | 2003-07-31 | Gelatin capsule exhibiting reduced cross-linking |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002493974A Abandoned CA2493974A1 (en) | 2002-07-31 | 2003-07-31 | Pharmaceutical dosage form comprising a sulfite compound |
| CA002494358A Abandoned CA2494358A1 (en) | 2002-07-31 | 2003-07-31 | Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002493980A Abandoned CA2493980A1 (en) | 2002-07-31 | 2003-07-31 | Gelatin capsule exhibiting reduced cross-linking |
Country Status (7)
| Country | Link |
|---|---|
| EP (4) | EP1526845A2 (pt) |
| JP (4) | JP2005538994A (pt) |
| AU (4) | AU2003257103A1 (pt) |
| BR (4) | BR0312875A (pt) |
| CA (4) | CA2493974A1 (pt) |
| MX (4) | MXPA05000862A (pt) |
| WO (4) | WO2004010972A2 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8895059B2 (en) | 2002-06-05 | 2014-11-25 | Ivax Pharmaceuticals S.R.O. | Reduction of cross-linking gelatin in gelatin capsules |
| KR101364762B1 (ko) | 2005-02-17 | 2014-02-17 | 신타 파마슈티칼스 코프. | 증식성 장애의 치료를 위한 화합물 |
| US7485323B2 (en) | 2005-05-31 | 2009-02-03 | Gelita Ag | Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions |
| DK1906938T3 (da) * | 2005-07-26 | 2011-02-07 | Nicox Sa | Farmaceutisk formulering af nitrooxyderivater af NSAID'er |
| JP5503939B2 (ja) * | 2009-10-16 | 2014-05-28 | 東洋カプセル株式会社 | アゼラスチン塩酸塩含有カプセル剤 |
| JP6887456B2 (ja) | 2018-07-04 | 2021-06-16 | キャプシュゲル・ベルジウム・エヌ・ヴィ | 白色化剤として界面活性剤又は界面活性剤と塩を含有する皮膜形成性組成物 |
| US11364478B2 (en) * | 2019-05-22 | 2022-06-21 | Mezzimatic, LLC | Method of manufacturing throwable paintballs and paintballs made therefrom |
| WO2022119269A1 (ko) * | 2020-12-01 | 2022-06-09 | 주식회사 엘지화학 | 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 안정한 경구용 제제 |
| CN113230241A (zh) * | 2021-06-11 | 2021-08-10 | 北京畅盛医药科技有限公司 | 三羟甲基氨基甲烷盐在治疗心脑血管病的药物中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5115094B2 (pt) * | 1972-11-01 | 1976-05-14 | ||
| US4349529A (en) * | 1980-04-14 | 1982-09-14 | E. R. Squibb & Sons, Inc. | Diagnostic and therapeutic capsules and method of producing |
| US4590183A (en) * | 1985-04-22 | 1986-05-20 | Sterling Drug Inc. | Gastric cytoprotection with sodium thiosulfate in oral administration of aspirin |
| FR2617047B1 (fr) * | 1987-06-23 | 1991-05-10 | Sanofi Sa | Composition de gelatine resistant au tannage, capsules a base de cette composition et leur application pharmaceutique, notamment au fenofibrate |
| JP2790659B2 (ja) * | 1989-06-30 | 1998-08-27 | 帝国臓器製薬株式会社 | ゼラチンカプセル剤 |
| CN1091597C (zh) * | 1994-03-15 | 2002-10-02 | 千寿制药株式会社 | 稳定双吡苯丙酸的方法和稳定的双吡苯丙酸液体制剂 |
| IT1269583B (it) * | 1994-04-26 | 1997-04-08 | Bayer Italia Spa | Preparazioni farmaceutiche a base di una soluzione di ketoprofene in capsule di gelatina molle e metodo per la loro produzione |
| PT695544E (pt) * | 1994-08-05 | 2001-03-30 | Shionogi & Co | Capsulas de gelatina dura resistentes a desnaturacao e sua producao |
| US5620704A (en) * | 1994-11-07 | 1997-04-15 | Warner-Lambert Company | Process for stabilizing gelatin products |
| US7115565B2 (en) * | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
-
2003
- 2003-07-31 EP EP03772160A patent/EP1526845A2/en not_active Withdrawn
- 2003-07-31 WO PCT/US2003/024042 patent/WO2004010972A2/en not_active Application Discontinuation
- 2003-07-31 MX MXPA05000862A patent/MXPA05000862A/es not_active Application Discontinuation
- 2003-07-31 BR BR0312875-0A patent/BR0312875A/pt not_active IP Right Cessation
- 2003-07-31 AU AU2003257103A patent/AU2003257103A1/en not_active Abandoned
- 2003-07-31 EP EP03772159A patent/EP1526844A2/en not_active Withdrawn
- 2003-07-31 WO PCT/US2003/024043 patent/WO2004010973A2/en active Application Filing
- 2003-07-31 JP JP2004524262A patent/JP2005538994A/ja not_active Withdrawn
- 2003-07-31 AU AU2003257981A patent/AU2003257981A1/en not_active Abandoned
- 2003-07-31 WO PCT/US2003/024045 patent/WO2004010974A2/en active Application Filing
- 2003-07-31 MX MXPA05001272A patent/MXPA05001272A/es unknown
- 2003-07-31 CA CA002493974A patent/CA2493974A1/en not_active Abandoned
- 2003-07-31 WO PCT/US2003/024044 patent/WO2004022032A2/en active Application Filing
- 2003-07-31 AU AU2003257982A patent/AU2003257982A1/en not_active Abandoned
- 2003-07-31 CA CA002494358A patent/CA2494358A1/en not_active Abandoned
- 2003-07-31 BR BR0313150-5A patent/BR0313150A/pt not_active IP Right Cessation
- 2003-07-31 CA CA002494069A patent/CA2494069A1/en not_active Abandoned
- 2003-07-31 JP JP2004524261A patent/JP2005538993A/ja not_active Withdrawn
- 2003-07-31 MX MXPA05001166A patent/MXPA05001166A/es unknown
- 2003-07-31 MX MXPA05001167A patent/MXPA05001167A/es unknown
- 2003-07-31 JP JP2004534259A patent/JP2006500389A/ja not_active Withdrawn
- 2003-07-31 AU AU2003257102A patent/AU2003257102A1/en not_active Abandoned
- 2003-07-31 BR BR0313149-1A patent/BR0313149A/pt not_active IP Right Cessation
- 2003-07-31 EP EP03794452A patent/EP1526847A2/en not_active Withdrawn
- 2003-07-31 EP EP03772161A patent/EP1526846A2/en not_active Withdrawn
- 2003-07-31 CA CA002493980A patent/CA2493980A1/en not_active Abandoned
- 2003-07-31 JP JP2004524263A patent/JP2005538102A/ja not_active Abandoned
- 2003-07-31 BR BR0313064-9A patent/BR0313064A/pt not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20040131670A1 (en) | Pellicle-resistant gelatin capsule | |
| EP1492527B1 (en) | Process for preparing a finely self-emulsifiable pharmaceutical composition | |
| US20030105141A1 (en) | Finely self-emulsifiable pharmaceutical composition | |
| AU2002305175A1 (en) | Orally deliverable pharmaceutical composition comprising a drug of low water solubility (COX-2 inhibitor), a solvent, a fatty acid and an organic amine | |
| US20040105885A1 (en) | Gelatin capsule exhibiting reduced cross-linking | |
| SA90100287B1 (ar) | كبسولات صيدلية تحتوي على رانيتيدين | |
| CA2494069A1 (en) | Pellicle-resistant gelatin capsule | |
| JPS6024767B2 (ja) | 腸溶性硬カプセル剤 | |
| JP2008543851A (ja) | 催吐剤封入カプセル | |
| US20040105884A1 (en) | Pharmaceutical dosage form comprising a sulfite compound | |
| ZA200404788B (en) | Pharmaceutical composition for oral administration. | |
| US20210378970A1 (en) | Pharmaceutical dosage form for an emulsion of simethicone and loperamide | |
| ZA200307575B (en) | Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2inhibitor), a solvent, a fatty acid and an organic amine. | |
| AU2002243535B2 (en) | Pharmaceutical composition having reduced tendency for drug crystallization | |
| CA2098410A1 (en) | Pharmaceutical soft capsules containing lysine clonixinate and a process for their preparation | |
| AU2002243535A1 (en) | Pharmaceutical composition having reduced tendency for drug crystallization |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |